The American Cancer Society estimates that about 67,440 Americans (34,950 men and 32,490 women) will be diagnosed with ...

A rapid nanosensor assay that measures serum protease cleavage of a target-probe nanosensor can identify pancreatic du ...

Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...

Pancreatic cancer is one of the deadliest types of cancer, with fewer than 13% of people diagnosed with it surviving for more ...

A new study from Memorial Sloan Kettering Cancer Center shows good results for patients with pancreatic cancer. They used a ...

A new type of mRNA vaccine, added to standard cancer treatment, could help some patients with pancreatic cancer live longer.

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by ...

As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

Clinical studies suggest that the mRNA vaccine may play a role in treating pancreatic cancer, identified as one of the most ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...